Evidence brief
MOTS-c: Mitochondrial-peptide research and human-evidence limits
This research brief explains the difference between observational human work and intervention evidence. It does not provide exercise, treatment, or product advice.
Evidence maturity: preclinical research dominates; human intervention evidence remains limited.
Human evidence
The cited work includes human observational and translational context, not an established clinical use of administered MOTS-c. Association findings do not establish benefit or safety from a product.
Preclinical context
Experimental work investigates mitochondrial-derived peptide signaling and metabolic pathways. These hypotheses require separate human outcome research.
What remains unknown
Large randomized trials, long-term safety information, standardized preparations, and clinically validated indications remain absent from the cited evidence base.
Human-evidence table
A structured reading aid, not a treatment or product decision tool.
| Evidence maturity | Human-study context | Interpretation limit |
|---|---|---|
| preclinical research dominates; human intervention evidence remains limited. | The cited work includes human observational and translational context, not an established clinical use of administered MOTS-c. Association findings do not establish benefit or safety from a product. | Large randomized trials, long-term safety information, standardized preparations, and clinically validated indications remain absent from the cited evidence base. |
Canadian regulatory context
Health Canada’s advisory on unauthorized injectable peptide drugs provides general safety context. This page does not assess a product or recommend any intervention.
Evidence timeline
- 1
2010s: mitochondrial-derived peptide research expands
- 2
2020: human translational observations reported
- 3
Current: intervention and long-term safety evidence remains limited
How to read this evidence brief
Population first
Start with the studied population and protocol before interpreting an outcome. A result in a defined disease group does not automatically generalize to other readers.
Outcome second
Separate measured endpoints from broader claims about health, performance, product quality, or long-term benefit.
Limitations remain visible
The evidence gaps and regulatory context are part of the record, not footnotes to be ignored.
Sources and maintenance
Sources are linked directly so readers can review the original material and its limitations.
- Human translational study
Primary research on MOTS-c biology and human context.
- Mitochondrial-derived peptide review
Review of evidence maturity and research questions.
- Health Canada public advisory
Official Canadian information on unauthorized injectable peptide drugs.